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A pulmonary nodule is a single, nearly spherical, well-circumscribed pulmonary opacity up to 30 mm in
diameter and surrounded by aerated lung tissue. In radiographs, pulmonary nodules may appear as solid,
completely obscuring the lung parenchyma, or as subsolid, not completely obscuring adjacent tissues. A
subsolid pulmonary nodule may be further subclassified as a pure ground glass nodule (pGGN) or a part
solid nodule, a mixture of ground glass components and focal opacity obscuring the adjacent tissues.
Guidelines for evaluation of solid pulmonary nodules are based on nodule size, recommending vigilance and
non-operative management for small nodules (less than 8 mm in diameter) and diagnostic biopsy for nodules
with a diameter of 8 mm or more. However, subsolid ground glass pulmonary nodules are an exception to this
rule. Although small in size, persistent subsolid nodules are potentially premalignant or malignant. We
present the case of a non-smoker who was found to have an incidental pulmonary pGGN. We then discuss the
radiologic appearance, histology, clinical outcomes, and evaluation and management strategy of subsolid
pulmonary nodules compared with solid nodules.
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A
55-year-old man with a medical history of hy-
pertension and hyperlipidemia was referred to
a pulmonologist for evaluation of a persistent
asymptomatic pulmonary nodule. Seven months before
presentation, an abdominal CT scan obtained to evaluate
constant perirectal pain showed a pure ground glass nodule
(pGGN), 2.42.6 cm in size, in the left lower lobe of
the lung. At that time, chest CT confirmed the presence of
the pGGN and showed no other pulmonary lesions (Fig. 1).
A combined PET/CT scan showed no abnormal uptake
of FDG tracer by the nodule. Subsequently, the patient
underwent surgical resection of the perirectal abscess
and had an uneventful recovery. A 6-month follow-up
CT scan of the chest showed no change in the pulmonary
nodule and prompted the pulmonary consultation. The
patient had no prior history of pulmonary disease and no
exertional dyspnea, cough, wheeze, or other chest com-
plaints. The patient had no history of cigarette smoking
but reported occasional pipe smoking in the remote
past. His examination showed normal vital signs, oxygen
saturation of 98% while inspiring room air, and an entirely
normal lung and general physical examination.
The pulmonary consultant and the thoracic surgeon
he consulted agreed that the appearance of this nodule
was suspicious for malignancy and gave the patient the
options of early surgical resection versus ongoing ob-
servation. Based on personal preference, the patient opted
for early surgical resection. On histologic examination,
the surgical specimen revealed moderately differentiated
papillary adenocarcinoma (Fig. 2). The patient had an
uneventful recovery from the surgery and no other treat-
ment was recommended. He remains disease free at 3 years
after surgery.
The clinical decision in this case, which was made 4
years ago, is consistent with the 2013 management al-
gorithm (1) for subsolid pulmonary nodules, which is
discussed below.
Discussion
A pulmonary nodule is a single, nearly spherical,
well-circumscribed pulmonary opacity up to 30 mm
indiameter and surrounded by aerated lung tissue (2).
Pulmonary nodules may appear as solid, completely
obscuring the lung parenchyma, or as subsolid, not com-
pletely obscuring adjacent tissues. A subsolid pulmo-
nary nodule may be further subclassified as a pGGN or a
part solid nodule, a mixture of ground glass components
and focal opacity obscuring the adjacent tissues (Fig. 3).
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are subsolid (3).
Subsolid nodules may be benign [such as inflamma-
tory, hamartoma, focal hemorrhage, or focal interstitial
fibrosis (4)], or they may be malignant or premalignant.
Of subsolid nodules, 4070% resolve spontaneously in
3 months and upon resolution are presumed to have
been benign (5). Subsolid nodules that persist for more
than 3 months are considered potentially malignant, with
a crude malignancy rate for part solid nodules and
pGGN of 63% (10/16), and 18% (5/28), respectively,
compared with the rate of 7% (14/189) for solid nodules
(3). One study found that 75% of 53 non-resolving
pGGNs were either bronchoalveolar carcinomas (BAC)
or adenocarcinoma with a predominant BAC compo-
nent; 6% were atypical adenomatous hyperplasia (AAH),
and 19% were benign (6). AAH is a less common
pathologic finding in surgically resected pGGNs and
is a premalignant precursor of adenocarcinoma that is
characterized by proliferation of epithelial cells without
Fig. 1. Initial chest CT of the pulmonary nodule with lung
(a) and mediastinal window (b). A 2.42.6 cm pure ground
glass nodule (pGGN) was present in the left lower lobe of
the lung.
Fig. 2. The pathology slide from resection tissue reveals well-
differentiated papillary adenocarcinoma at the low power
ﬁeld (a). High-powered ﬁeld slide demonstrates the typical
acinar pattern of glandular differentiation (b). The tumor is
strongly and diffusely TTF-1 positive (c), as is characteristic
of primary adenocarcinoma of the lung.
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scribed in the 1999 and 2004 World Health Organization
classifications of lung adenocarcinoma as a type
of adenocarcinoma with lepidic growth pattern (along
intact alveolar septa) with minimal, if any, PET-FDG
uptake and occurring in relatively low-risk (such as
non-smoking) patients. Patients with BAC have varied
prognosis, with some having excellent survival and others
progressing from early stage to more advanced stage
during the 24 years before attempted surgical resection
(3, 8).
With the development of better correlation between
radiographic appearance of subsolid nodules and the
invasiveness of the tumor, in 2011 the International Asso-
ciation for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society (IASLC/ATS/
ERS) has reclassified BAC into the subtypes adenocarci-
noma in situ (AIS), minimally invasive adenocarcinoma
(MIA), and lepidic predominant adenocarcinoma (LPA)
(9). The new pathology terminology has been adopted to
betteridentifyBAConthecontinuumofpremalignantpre-
cursor (AAH), adenocarcinoma in situ (AIS and MIA),
Fig. 3. Classiﬁcation of pulmonary nodule.
Table 1. Guidelines for evaluation of pulmonary nodules
a
Pure GGN less than 8 mm
If less than 5 mm, no follow-up
If greater than 5 mm, annual CT for at least 3 years
Part solid nodules
If less than 8 mm, CT at 3, 12, 24 months, then annual CT for 13 years
If greater than 8 mm, repeat CT at 3 months, followed by PET, needle biopsy, and/or surgical resection
Solid nodules less than 8 mm without risk factors
If less than 4 mm, no follow-up
If 46 mm, reevaluate at 12 months, if unchanged
If 68 mm, reevaluate between 6 and 12 months, then between 18 and 24 months, if unchanged
Solid nodules less than 8 mm with risk factors
If less than 4 mm, reevaluate at 12 months
If 46 mm, reevaluate between 6 and 12 months, then between 18 and 24 months, if unchanged
If 68 mm, reevaluate between 3 and 6 months, then between 9 and 12 months, and again at 24 months, if unchanged
Solid nodules, 830 mm, with low to moderate pretest probability
Consider PET, needle biopsy as initial work up; if negative, then serial CT scans at 36, 912, 1824 months
Consider PET, needle biopsy as initial work up; if positive, then surgical resection unless contraindicated
Solid nodules, 830 mm, with high pretest probability
PET is not recommended to characterize the nodule, prefer surgical diagnosis
Dominant nodule and one or more additional small nodules
Each nodule should be evaluated individually; curative treatment not be denied unless proved to be metastasis
aTable summarizes diagnosis and management of pulmonary nodules as described by Gould et al. (1).
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AAH, AIS, or MIA have a good prognosis, with near
100% 5-yeardisease-free survivalaftercomplete resection.
Patients with LPA have 8690% 5-year disease-free
survival after surgical resection (10), whereas patients
with invasive adenocarcinoma have 67% 5-year disease-
free survival after surgical resection (11). The classifica-
tion system of early-stage pulmonary adenocarcinoma
may improve future clinical trials designed to stratify
patients to expectant observation, surgical resection, and/
or adjuvant chemotherapy.
In 2013, Gould et al. described a management algo-
rithm for individuals with both solid and subsolid pul-
monary nodules that takes into account size, radiologic
appearance, and independent risk factors for malignancy
(older age, current or past smoking history, and extra-
thoracic cancer) (1). Generally, the likelihood of invasive-
ness correlates with the initial size of the pulmonary
nodule [e.g., the prevalence of malignancy is less than
1% for nodules less than 5 mm in diameter, 628% for
nodules between 5 and 10 mm in diameter, and 6482%
for nodules over 20 mm in diameter (12)], observed
growth, or the development of a solid component within
the nodule. Certain pathologic types of pulmonary nod-
ules may correlate with radiographic appearance. For
example, AIS typically presents as a pGGN and MIA
is more likely to present as a part solid nodule, whereas
invasive adenocarcinomas may present as a solid nodule,
a part solid nodule, or occasionally a pGGN (9).
Studies support using this more stringent evaluation
and treatment algorithm for subsolid pulmonary nodules.
A study showed that 59% of 320 subsolid malignant
nodules occur in never-smokers, whereas 25% of solid
malignant nodules occurred in never-smokers, a statis-
tically significant difference (13). A recent study of 46
resected pGGNs using the new classification system
found that 41% were AISs, 20% were MIAs, and 39%
were invasive adenocarcinomas (14). Although PET scan
has relatively good sensitivity and specificity (87 and
83%, respectively) for distinguishing cancer from non-
cancer in solid pulmonary nodules (1), the sensitivity
of PET scan in subsolid nodules is lower (50%) (15, 16).
Also, the accuracy of transthoracic biopsy is lower in
patients with pGGNs, with accuracy rates of (67, 85, and
95% for pGGNs, subsolid nodules, and solid nodules,
respectively) (17). The current case highlights the im-
portance of early consideration of surgical resection for
subsolid pulmonary nodules consistent with the 2013
management guidelines (1) (Table 1).
However, further studies are needed to weigh the
benefits and risks of immediate surgical resection versus
serial low-dose CT scan follow-up and to determine
the optimal duration of CT scan follow-up for those
patients not undergoing immediate resection. Based on
our current understanding of the radiographic, pathologic,
and clinical correlates of subsolid nodules, clinicians
should consider an individualized diagnostic strategy
accounting for the nodule’s radiographic characteristics
and the patient’s comorbidities and personal preferences.
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